The entry pathway of the human immunodeficiency virus type-1 (HIV-1) can be divided into three major events: binding, activation and fusion. The viral envelope protein is essential for each of these stages; it consists of a surface subunit, gp120, and a transmembrane subunit, gp41, which form an oligomeric complex in the virion membrane [1] . The gp120 subunit contains a binding domain specific for the human CD4 molecule, the cellular receptor for HIV-1. The gp41 subunit contains a fusogenic hydrophobic peptide at its amino terminus, which is essential for fusion of the viral and cellular membranes. The primary cell types infected by HIV -helper T cells, macrophages and dendritic cells -all express CD4, which is thus a fundamental determinant of both the species and cellular tropism of HIV-1. The CD4-gp120 interaction is thought to activate the fusion activity of the envelope oligomer by inducing a conformation shift [2, 3] that exposes new functional domains, such as the third variable region (V3) of gp120. The consequent fusion of the viral and plasma membranes releases the viral core into the cell to initiate replication. The CD4-gp120 interaction is thus important for the first two major steps in the HIV entry pathway; it provides a high affinity binding receptor and is involved in activating the fusion activity of the viral envelope.
Soon after CD4 was identified as the cellular receptor for HIV-1, it became clear that expression of CD4 alone is insufficient for envelope-mediated fusion to occur. One test of this is to transfect a cell line with the CD4 gene, and see if it confers the ability to fuse with cells expressing the HIV-1 gp120 protein. A small number of human cell lines, and the vast majority of non-human cell lines, fail this test [4, 5] ; the human cell lines that fail are classed as 'restrictive', as opposed to the 'permissive' cell lines that pass the test when they express CD4. The restrictive CD4 + cells were also found to resist infection by cell-free virus particles, as a result of a block at the level of virus entry [6] [7] [8] . The fusion defect of the restrictive CD4 + cells can, however, be complemented by prior fusion with permissive CD4 -cells, indicating that the block to fusion is the result of the lack of a cofactor in some cell types [9] [10] [11] .
The expression of different fusion cofactors by various cell types has been shown to be a major determinant of HIV-1 tropism [12] . The tropism of different HIV-1 strains is primarily distinguished on the basis of their ability to infect monocyte-derived macrophages as opposed to established T-cell lines. Macrophage-tropic viruses are thought to be fundamental for the transmission and pathogenesis of HIV-1; for example, macrophagetropic viruses have been shown to predominate early in infection, possibly as a result of selection during transmission when the initial cellular targets of an infection are tissue macrophages or dendritic cells. Macrophages are also believed to facilitate the dissemination of virus to various tissues within an infected individual, and thereby to contribute to the pathological course of the infection. On the virus side, important determinants of tropism have been mapped to the V3 region of gp120 [13] . Until recently, the cellular determinants of tropism were not known, but several different fusion cofactors have now been identified and established as the cellular basis for the specificity of the fusion reaction [14] [15] [16] [17] [18] [19] [20] .
The first fusion cofactor to be identified was specific for virus strains adapted to T-cell lines [14] , and proved to be a member of the seven transmembrane G-protein-coupled receptor superfamily. Several laboratories investigating that superfamily had previously isolated cDNAs for the same receptor, but had been unable to determine its ligand. Because of its role as a fusion cofactor, the protein has been dubbed 'fusin', but this may be a temporary appellation pending identification of its natural ligand. Sequence analysis shows that fusin has ~35 % sequence similarity to interleukin 8 (IL-8) receptor-␤, and so is likely to be the receptor for an as yet undefined chemokine. As expected, fusin was found to be required for cell fusion mediated by the envelope protein of laboratory-adapted isolates. In addition, expression of fusin on non-permissive cell types allowed infection by cell free T-cell-tropic viruses, but not by macrophage-tropic isolates [14] .
The discovery that fusin is related to chemokine receptors provided the catalyst for a dramatic convergence between studies of HIV-1 tropism and cell entry and investigations into the nature of antiviral factors released by CD8 (cytotoxic) T cells. Before the discovery of fusin, three ␤-chemokines -RANTES, MIP-1␣ and MIP-1␤ -had been shown to have anti-viral activity [15] . Following this lead, the receptors for other chemokines were screened for their ability to act as cofactors for viral entry. Thus, CC-CK5, a ␤-chemokine receptor specific for RANTES, MIP-1␣ and MIP-1␤, was shown to be a fusion cofactor for macrophage-tropic viral isolates [16] [17] [18] . Furthermore, the same three ␤-chemokines were found to block envelope-induced fusion mediated by CC-CKR5 but not by fusin. Additional chemokine receptors, CCCKR2b and CC-CKR3, can also be used as cofactors by some HIV-1 isolates [19, 20] and by HIV-2 (Mark Marsh, personal communication).
Although the potential role that these additional cofactors play in vivo during an infection remains to be determined, compelling evidence for the importance of CC-CKR5 in vivo has been reported very recently [21, 22] . Individuals possessing HIV-1-resistant CD4 T cells have been identified because they have remained seronegative for HIV-1 despite having a high risk of infection [23] . The genetic basis for their resistance to HIV-1 has now been shown to be due to the disruption of both of their CKR5 alleles by a short deletion [21] . Even individuals heterozygous for the mutation in CKR5 appear to be partially resistant to infection [22] , due either to an inhibitory effect of the mutation or decreased expression of functional CC-CKR5. The finding that a mutation in CKR5 renders individuals resistant to infection underscores the importance of the interaction of macrophage-tropic viruses with the CC-CKR5 cofactor during HIV-1 transmission. Consequently, the development of agents that block the interaction with CC-CKR5 is a new and promising approach to HIV-1 prophylaxis
The finding that various subsets of fusion cofactors are used by different viral isolates provides a satisfying explanation for the complex tropism patterns exhibited by HIV-1. Indeed, the established tropisms of many viral strains indicate that more fusion cofactors remain to be identified. The identification of new cofactors will also be facilitated by the development of neutralizing monoclonal antibodies against existing cofactors; for example, a neutralizing monoclonal antibody against fusin blocks HIV-1 infection of some T-cell lines but not others, suggesting that some T-cell lines may express additional, undefined cofactors (Jim Hoxie and Paul Clapham, personal communication).
The mechanism by which cofactors facilitate fusion will now be the focus of considerable investigation, for understanding the exact role played by chemokine receptors during virus entry will assist their exploitation as potential therapeutic targets. As predicted from tropism studies, the gp120 V3 loop is an important determinant of cofactor usage [19] , and consequently also of susceptability to viral suppression by chemokines [23] . It is interesting to note that other retroviruses, such as murine leukaemia virus (MLV), use cellular receptors that, like chemokine receptors, have small extracellular domains [1] . In the case of HIV-1, therefore, it might be that binding to a long rodlike molecule, such as CD4, provides an efficient receptor for adsorption, but that binding to a cofactor close to the lipid bilayer is required for the subsequent events leading to membrane fusion. One challenge now will be to understand how the conformational changes induced by consecutive gp120 binding to its two receptors trigger gp41 to mediate the final fusion event (Fig. 1 ).
An additional and provocative possibility is that binding by gp120 V3 region to the fusion cofactor transduces a signal to the target cell via the G-protein-coupled pathway. A The HIV-1 cell-entry pathway. Specific binding of CD4 by gp120 triggers a cascade of interactions that result in virus entry. CD4 binding induces a conformational shift in gp120 which is followed by binding to a specific cofactor, determined by the V3 region of gp120. Only after binding to the cofactor does the fusion of viral and cellular membranes occur, mediated by insertion into the cell membrane of the fusogenic peptide at the amino terminus of gp41. The precise mechanism by which cofactor binding to gp120 leads to activation of gp41 is not known but, as gp120 is thought to occlude the fusion peptide in gp41, it is likely to involve additional conformational changes that lead to the dissociation of gp41 and gp120.
stimulatory signal generated during entry could possibly play a role in the infection of non-proliferating cells such as macrophages. Another possibility is that a signal transduced during entry could induce newly infected dendritic cells to migrate, or express cell-surface molecules enhancing their retention by proximal lymph nodes. A more thorough understanding of the mechanism of fusion is also required to explain the differences between cell-cell fusion and cell-free infection that have been described. For example, macrophages express fusin and also support syncytia formation with cells infected with T-cell-tropic HIV-1 isolates, but entry of the same viral isolates is blocked in macrophages [24] .
Understanding the entry process has important implications for our understanding of several key aspects of HIV-1 transmission and pathogenesis. It has also opened up new avenues for therapeutic intervention and prophylaxis. Several uninfected high-risk individuals have been shown to have elevated levels of ␤-chemokines, suggesting that ␤-chemokines may provide protection against infection [23] . In light of this finding, the induction of protracted ␤-chemokine production could become an aim of vaccine design. The development of new small animal models for HIV-1 infection is another goal made feasible by the identification of fusion cofactors. But it remains to be seen whether creating transgenic animals expressing a selected few cofactors will produce a satisfactory model for a virus infection which in the natural host probably involves many cofactors. Nevertheless, the recent discoveries of crucial cofactors for HIV-1 entry into cells clearly promise to open many more doors to an increased understanding of HIV biology.
